MX342548B - Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. - Google Patents

Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.

Info

Publication number
MX342548B
MX342548B MX2012003310A MX2012003310A MX342548B MX 342548 B MX342548 B MX 342548B MX 2012003310 A MX2012003310 A MX 2012003310A MX 2012003310 A MX2012003310 A MX 2012003310A MX 342548 B MX342548 B MX 342548B
Authority
MX
Mexico
Prior art keywords
opioid
opioid receptor
compound
gastrointestinal tract
receptor antagonist
Prior art date
Application number
MX2012003310A
Other languages
English (en)
Other versions
MX2012003310A (es
Inventor
M Woodward Richard
Original Assignee
Merck Sharp & Dohme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342548(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp * filed Critical Merck Sharp & Dohme Corp *
Publication of MX2012003310A publication Critical patent/MX2012003310A/es
Publication of MX342548B publication Critical patent/MX342548B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un método para tratar o prevenir una condición en un sujeto asociada con la activación de un receptor opiáceo en la periferia administrando una cantidad efectiva de 5-(2-metoxi-4-{[2-(tetrahidro-piran-4-il)-etilamino]-m etil}-fenoxi)-pirazin-2-carboxamida (Compuesto I). En particular, la descripción se relaciona con un método para tratar o prevenir el estreñimiento inducido por opiáceo o disfunción del intestino inducida por opiáceo en un humano sin reducir la analgésia del opiáceo mediada centralmente o producir síntomas de abstinencia del opiáceo central administrando una cantidad efectiva del Compuesto (I). La descripción además se relaciona al uso del Compuesto (I) para la preparación de un fármaco para el tratamiento o prevención de una condición en un sujeto asociada con la activación de un receptor opiáceo en la periferia.
MX2012003310A 2009-09-18 2010-09-17 Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. MX342548B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (2)

Publication Number Publication Date
MX2012003310A MX2012003310A (es) 2012-07-17
MX342548B true MX342548B (es) 2016-10-04

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003310A MX342548B (es) 2009-09-18 2010-09-17 Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.

Country Status (19)

Country Link
US (1) US20110071163A1 (es)
EP (1) EP2477627B1 (es)
JP (1) JP5797655B2 (es)
KR (1) KR20120092592A (es)
CN (2) CN104958298A (es)
AU (1) AU2010295464B2 (es)
BR (1) BR112012006069A8 (es)
CA (1) CA2774021A1 (es)
CL (1) CL2012000676A1 (es)
CO (1) CO6531453A2 (es)
HK (1) HK1210959A1 (es)
IL (1) IL218679A0 (es)
MX (1) MX342548B (es)
NZ (1) NZ598783A (es)
PE (1) PE20120991A1 (es)
RU (1) RU2561873C2 (es)
TW (1) TW201118084A (es)
WO (1) WO2011035142A1 (es)
ZA (1) ZA201201954B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2760880E (pt) 2012-12-28 2015-10-27 Inst Medycyny Doswiadczalnej I Klinicznej Peptidomiméticos e sua aplicação
WO2017198339A1 (en) 2016-05-20 2017-11-23 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1995028963A1 (fr) 1994-04-22 1995-11-02 Yamanouchi Pharmaceutical Co., Ltd. Systeme de liberation de medicament specifique au colon
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ES2234306T3 (es) 1998-09-28 2005-06-16 Warner-Lambert Company Llc Administracion enterica y via colon usando capsulas de hpmc.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
TR200201032T2 (tr) * 1999-10-15 2002-08-21 Sucampo Ag yeni terkip ve stabilizasyon yöntemi.
CA2389650C (en) * 1999-11-01 2008-12-09 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
WO2002036573A2 (en) * 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
BR0212233A (pt) * 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
KR100974842B1 (ko) * 2001-10-18 2010-08-11 넥타르 테라퓨틱스 아편양 길항제의 중합체 공액
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
BRPI0314308B8 (pt) * 2002-09-19 2021-05-25 Lilly Co Eli antagonistas de opióide, seus usos, e composição farmacêutica
EP2281564A3 (en) * 2002-12-27 2012-09-05 Sucampo AG Derivatives of prostaglandins for treating abdominal discomfort
CA2513791A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
MXPA06007198A (es) * 2003-12-22 2006-09-04 Lilly Co Eli Antagonistas de receptor opioide.
CA2558568A1 (en) * 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
WO2005090337A1 (en) * 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
BRPI0707334B8 (pt) * 2006-01-24 2021-05-25 R Tech Ueno Ltd formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
JP5403762B2 (ja) * 2007-12-11 2014-01-29 セラヴァンス， インコーポレーテッド μオピオイド受容体アンタゴニストとしての３−カルボキシプロピル−アミノテトラリン誘導体
SG172016A1 (en) * 2008-12-10 2011-07-28 Theravance Inc Crystalline forms of a 3-carboxypropyl-aminotetralin compound
EP2506712B8 (en) * 2009-12-04 2019-06-19 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose

Also Published As

Publication number Publication date
TW201118084A (en) 2011-06-01
JP2013505260A (ja) 2013-02-14
RU2561873C2 (ru) 2015-09-10
KR20120092592A (ko) 2012-08-21
AU2010295464B2 (en) 2015-11-26
HK1210959A1 (en) 2016-05-13
US20110071163A1 (en) 2011-03-24
CO6531453A2 (es) 2012-09-28
AU2010295464A1 (en) 2012-04-12
NZ598783A (en) 2013-07-26
MX2012003310A (es) 2012-07-17
WO2011035142A1 (en) 2011-03-24
RU2012115450A (ru) 2013-10-27
CA2774021A1 (en) 2011-03-24
PE20120991A1 (es) 2012-08-01
CN102695508A (zh) 2012-09-26
EP2477627A1 (en) 2012-07-25
CN104958298A (zh) 2015-10-07
BR112012006069A2 (pt) 2016-03-29
IL218679A0 (en) 2012-05-31
EP2477627B1 (en) 2018-08-15
BR112012006069A8 (pt) 2017-10-10
ZA201201954B (en) 2012-11-28
JP5797655B2 (ja) 2015-10-21
CL2012000676A1 (es) 2012-10-19

Similar Documents

Publication Publication Date Title
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MX2012004848A (es) Compuestos heterociclicos triciclicos.
NZ580963A (en) Compositions and methods for prophylaxis and treatment of addictions
WO2007056300A3 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
NZ600379A (en) Morphinan derivatives for the treatment of drug overdose
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
WO2010080756A3 (en) Harmine derivatives for reducing body weight
MX2012014934A (es) Antagonistas de ciclohexilacetindinilo del receptor de la citocina quimioatrayente 2.
WO2011020030A3 (en) Methods and compositions to prevent addiction
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
GB2477256A (en) Medicament and method of diagnosis
WO2012012410A3 (en) Kappa opioid receptor agonists
MX2013006070A (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
MX2012003310A (es) Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
WO2011044375A3 (en) Apogossypolone derivatives as anticancer agents
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration